Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center

Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617. doi: 10.1016/j.cgh.2020.02.017. Epub 2020 Feb 14.

Abstract

The global incidence of inflammatory bowel disease (IBD) has increased considerably during the past few decades.1 IBDs, composed of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by heterogeneous presentation and widely variable clinical course. The therapeutic goals are to induce and maintain remission. Despite the current treatments available, many patients do not achieve this goal.

MeSH terms

  • Biological Therapy
  • Colitis, Ulcerative* / drug therapy
  • Crohn Disease* / drug therapy
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Tertiary Care Centers